Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Dyne Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Dyne Therapeutics, Inc.

DYN

Dyne Therapeutics, Inc.

About Dyne Therapeutics, Inc.

Dyne Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for neuromuscular and genetic muscle diseases. Utilizing its proprietary FORCE platform, it creates conjugates of antibodies, linkers, and payloads—such as oligonucleotides and enzymes—to deliver disease-modifying treatments to muscle tissue and the CNS. Its portfolio includes therapies for DM1, DMD, FSHD, and Pompe disease, focusing on genetic targets with high unmet medical needs.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Dyne Therapeutics, Inc.

1
1
Dyne Therapeutics, Inc. Dyne Therapeutics Reports $120.9 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Dyne Therapeutics, Inc. Dyne Therapeutics Reports $446.2 Million Net Loss for 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Dyne Therapeutics, Inc. Dyne Therapeutics Reports $334.3 Million Net Loss and Increased R&D Expenses for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Dyne Therapeutics, Inc. Dyne Therapeutics Reports $110.9 Million Net Loss in Q2 2025, Increases R&D Spending

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
Dyne Therapeutics, Inc. Dyne Therapeutics Reports $115.4 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Dyne Therapeutics, Inc. Dyne Therapeutics Reports Significant Asset Growth, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments